Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16998624 | 0.99 | ALDH1A1 (0.40) | LMNAALDH1A1MAPK1NPSR1HTT | |
| SCHEMBL859233 | 0.92 | HSP90AA1 (0.37) | LMNAALDH1A1MAPK1NPSR1HTT | |
| SCHEMBL844043 | 0.91 | HSP90AA1 (0.38) | LMNAALDH1A1MAPK1NPSR1HTT | |
| Hydrochloric Acid SCHEMBL859010 | 0.90 | HSP90AA1 (0.38) | LMNAALDH1A1MAPK1NPSR1HTT | |
| SCHEMBL16998609 | 0.76 | LMNA (0.47) | LMNAALDH1A1MAPK1HTTKDM4E | |
| SCHEMBL21338116 | 0.73 | LMNA (0.44) | LMNAALDH1A1MAPK1HTTKDM4E | |
| SCHEMBL16743436 | 0.73 | ALDH1A1 (0.40) | LMNAALDH1A1MAPK1NPSR1HTT | |
| SCHEMBL16743425 | 0.72 | LMNA (0.43) | LMNAALDH1A1MAPK1HTTKDM4E | |
| SCHEMBL21338228 | 0.71 | ALDH1A1 (0.38) | LMNAALDH1A1MAPK1NPSR1HTT | |
| SCHEMBL16998628 | 0.70 | LMNA (0.41) | LMNAALDH1A1MAPK1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | LMNA 2913/4885ALDH1A1 577/4885MAPK1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.